- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06160284
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
Study Overview
Detailed Description
Participants will undergo screening as outpatients at the Clinical Neuroscience Research Unit (CNRU). Once deemed eligible, OUD subjects will be studied as inpatients. However, they will have the option of scheduling their second [11C]-UCB-J PET as an outpatient (pending these participants' agreement to undergo outpatient visits twice per week to provide urine toxicology to monitor abstinence before PET).
The only portion of the study that will be available as outpatient for OUD subjects will be the 1-2 weeks before the second [11C]-UCB-J PET scan. The subject will still be admitted for 1-2 weeks, which will include: inpatient detoxification, baseline [11C]-UCB-J PET scan, psilocybin administration, and overnight observation after psilocybin administration. However, they may be discharged the day following psilocybin administration and return 2x weekly for urine toxicology testing between discharge and the second [11C]-UCB-J PET to confirm abstinence.
Structural magnetic resonance imaging (MRI) scans will be obtained for anatomical registration/partial volume correction from all subjects. Functional MRI (fMRI) scans will be completed pre- and post-psilocybin administration to evaluate changes in resting state connectivity. All subjects will participate in a battery of behavioral assessments for exploratory correlations with [11C]-UCB-J. Inpatient subjects who smoke cigarettes will have the option of using nicotine gum and/or nicotine patch while on the unit in order to prevent or minimize nicotine withdrawal. The [11C]-UCB-J PET scans will be done at the Yale PET Center 1-2 weeks before (baseline) and after psilocybin administration.
This is a single-center study at Yale, that will have study activities completed at the following areas:
- Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center (CMHC)
- Yale Positron Emission Tomography (PET) Imaging Center
- Yale Magnetic Resonance Research Center (MRRC)
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Gustavo Angarita, MD, MHS
- Phone Number: (203) 974-7536
- Email: gustavo.angarita@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntary, written, informed consent;
- Physically healthy by medical history, physical, neurological, ECG, and laboratory examinations;
- DSM-5 criteria for Opioid Use Disorder;
- Documented evidence (by urine toxicology) of opioid use (upon screening);
- Inpatient verified > 1 week of abstinence;
- For females, a negative serum pregnancy (beta-HCG) test.
Exclusion Criteria:
- DSM-5 criteria for other substance use disorders (e.g., alcohol, cocaine, sedative hypnotics), except for nicotine (concurrent alcohol or drug use is allowed if it does not meet criteria for a substance use disorder and does not take place during inpatient stay)
- A primary DSM-5 Axis I diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression, as determined by psychiatric history (Mini International Neuropsychiatric Interview, MINI), or another disorder that may interfere with the study's primary outcomes in the view of PI
- Immediate (first-degree relative) family history of formally diagnosed schizophrenia or other psychotic disorders (e.g., delusional disorder, schizoaffective disorder), or bipolar I/II disorder
- A history of significant and/or uncontrolled medical or neurological illness
- Hypertension at screening defined as: systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg;
- History of cardiovascular disease, including but not limited to clinically significant coronary artery disease, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, angina pectoris, coronary artery bypass graft or artificial heart valve, stroke, transient ischemic attack, or any clinically significant arrhythmia
- Any clinically significant abnormal electrocardiogram (ECG) finding, such as findings suggestive of ischemia or infarct, complete bundle branch block, atrial fibrillation or other symptomatic arrhythmia, or predominantly non-sinus rhythm, at screening
- Resting QT interval with Fridericia's correction (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female) at Screening, or inability to determine QTcF interval
- Presence of risk factors for torsades de pointes, including: long QT syndrome, uncontrolled hypokalemia or hypomagnesemia, history of cardiac failure, history of clinically significant/symptomatic bradycardia, family history of idiopathic sudden death or congenital long QT syndrome, or concomitant use of a torsadogenic medication
- Current use of psychotropic and/or potentially psychoactive prescription medications considered to the investigators are likely to interfere clinically with human subject's safety (i.e., contraindicated drug-drug interactions with psilocybin) or scientifically (i.e., likely to influence or alter outcomes of the study)
- Medical contraindications to MRI procedures (e.g., ferromagnetic implants/foreign bodies, claustrophobia, etc.)
- Arterial Line Exclusion: Blood donation within eight weeks of the start of the study
- Arterial Line Exclusion: History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)
- Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits followed by the Yale PET Center (21CFR361.1).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Current OUD diagnosis + psilocybin
All participants will receive a [11C]-UCB-J PET scan and fMRI with in 1-2 weeks pre and post treatment with one dose of Psilocybin.
Intravenous lines will be used for phlebotomy and administration of the [11C]-UCB-J radiotracer.
On the PET scanning day, a radial arterial catheter may be inserted.
|
Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants < 70 kg) or 25 mg (among participants >70 kg).
Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline [11C]-UCB-J PET.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Synaptic Density
Time Frame: baseline and 1-2 weeks post treatment
|
Change in synaptic density pre- and post- psilocybin administration will be measured using [11C]-UCB-J PET (volume of distribution [VT] and binding potential [BPND]) among OUD.
The regions of interest (ROI) will be subregions of the prefrontal cortex identified by preclinical and preliminary clinical studies.
|
baseline and 1-2 weeks post treatment
|
Association between VT and BPND
Time Frame: up to 12 weeks
|
Association between VT and BPND assessed to determine whether changes in VT are associated with changes in BPND.
|
up to 12 weeks
|
Time to relapse
Time Frame: up to 12 weeks
|
Mean number of days to relapse assessed by self- report
|
up to 12 weeks
|
Urine toxicology post treatment
Time Frame: up to 12 weeks
|
The mean number of positive urine tests post treatment will be assessed.
Urine samples will be tested for the presence of opioids.
A positive test indicates opioid usage in the last 2 weeks.
|
up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in vital signs- heart rate (HR)
Time Frame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Mean change in heart rate measured in beats per minute during Psilocybin session
|
immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Change in vital signs- respiratory rate (RR)
Time Frame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Mean change in respiratory rate measured in breaths per minute during Psilocybin session
|
immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Change in vital signs- oxygen saturation
Time Frame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Mean change in percent oxygen saturation assessed using a pulse oximeter during Psilocybin session
|
immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Change in vital signs- systolic blood pressure
Time Frame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Mean change in systolic blood pressure in mmHg during Psilocybin session
|
immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Change in vital signs- diastolic blood pressure
Time Frame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Mean change in diastolic blood pressure in mmHg during Psilocybin session
|
immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Change in vital signs- body temperature
Time Frame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Mean change in body temperature in degrees Fahrenheit during Psilocybin session
|
immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
|
Total number of participants with treatment emergent adverse events
Time Frame: up to 12 weeks
|
Total number of participants with any treatment emergent adverse events while on study assessed using the Systematic Assessment for Treatment Emergent Events (SAFTEE).
|
up to 12 weeks
|
Change in Profile of Mood States (POMS) Score
Time Frame: approximately 30 and 150 minutes post Psilocybin treatment
|
POMS is a validated 30 item questionnaire used to assess an individual's mood states.
Total scores range from 0 to 120 with lower scores indicating a better mood state.
|
approximately 30 and 150 minutes post Psilocybin treatment
|
Change in Clinical Opioid Withdrawal Scale (COWS) Score
Time Frame: approximately 30 and 150 minutes post Psilocybin treatment
|
COWS is an 11-item scale to rate common signs and symptoms of opiate withdrawal and monitor these symptoms over time.
The summed score determines the stage/severity of opiate withdrawal and assess the level of physical dependence on opioids.
Score: 5- 12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal
|
approximately 30 and 150 minutes post Psilocybin treatment
|
Change in Subjective Opioid Withdrawal Scale (SOWS) Score
Time Frame: approximately 30 and 150 minutes post Psilocybin treatment
|
SOWS is a self-administered scale for opioid withdrawal symptoms.
It has16 symptoms whose intensity is rated on a scale of 0 (not at all) to 4 (extremely).
Mild Withdrawal = score of 1-10, Moderate withdrawal = 11-20, Severe withdrawal = 21-30
|
approximately 30 and 150 minutes post Psilocybin treatment
|
Change in Opioid Symptom Checklist (OSC)
Time Frame: approximately 30 and 150 minutes post Psilocybin treatment
|
The OSC is a 13-item opioid symptom checklist consisting of true/false questions designed to measure opioid effects (e.g., "My skin is itchy").
True scores are totaled up to acute opiate positive and negative symptoms and low true scores will mean not feeling any of the negative and positive symptoms.
|
approximately 30 and 150 minutes post Psilocybin treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gustavo Angarita, MD, MHS, Yale University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000036178
- P30DA046345 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
-
Virginia Commonwealth UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-use Disorder | Cocaine Use Disorder | Healthy Controls | Marijuana Use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
Clinical Trials on Psilocybin
-
Yale UniversityHeffter Research Institute; Ceruvia Lifesciences; CH TAC LLCCompleted
-
University of Wisconsin, MadisonTRYP TherapeuticsWithdrawn
-
Yale UniversityCeruvia LifesciencesCompleted
-
King's College LondonUniversity of CambridgeRecruitingAutism Spectrum DisorderUnited Kingdom
-
Section for Affective Disorders; Northern Stockholm...Karolinska Institutet; Vastra Gotaland Region; Region Örebro County; Uppsala University...Recruiting
-
Yale UniversityHeffter Research InstituteActive, not recruitingMajor Depressive DisorderUnited States
-
University Health Network, TorontoCentre for Addiction and Mental HealthRecruitingDepression | Mood Disorders | Major Depressive Disorder | Treatment-Resistant DepressionCanada
-
Yale UniversityTerminated
-
University of Colorado, DenverNot yet recruitingAnhedonia | Major Depressive Disorder | Treatment Resistant DepressionUnited States
-
Multidisciplinary Association for Psychedelic StudiesWithdrawnAnxiety | Stage IV MelanomaUnited States